

# JOINT VENTURE AGREEMENT

THIS JOINT VENTURE AGREEMENT (the "Agreement" or this "Joint Venture Agreement"), is made and entered into as of August 1<sup>st</sup>, 2017, by and between IMMUNEMED Inc. (hereinafter "IMMUNEMED"), a Korea corporation, with a registered office located at Rm# 2-2, Bldg# 3, Chuncheon Biotown, 32 Soyangganog-ro, Chuncheon, Gangwon-do, 24232, Republic of Korea, and PRIMA (Thailand) Co., Ltd (hereinafter "PRIMA") , a Thailand corporation, with a registered office located at 61/487 Bangyai City Center, Moo 6, Soathonghin, Bangyai, Nonthaburi, 11140, Thailand

WITNESSETH:

WHEREAS, "IMMUNEMED" is in the business of manufacturing and furnishing the diagnostic rapid kits, and

WHEREAS, "PRIMA" is in the business of selling the diagnostic rapid kits, and

WHEREAS, the parties desire to establish between them a joint venture in order to collaborate in Immunemed (Thailand) Co., Ltd.,

NOW, THEREFORE, in consideration of the foregoing, and of the mutual covenants and commitments set forth herein, the parties hereto agree as follows:

## 1. FORMATION

The joint venture formed by this Agreement (the "Joint Venture") will conduct its business under the name Immunemed (Thailand) Co., Ltd., and will have its registered address at No. 73/352, Mu 5, Sao Thong Hin Sub-district, Bang Yai District, Nonthaburi Province, Thailand. The Joint Venture shall be considered a joint venture between the Parties in all respects, and in no event shall this Agreement be construed to create a partnership or any other fiduciary relationship between the Parties.

## 2. PURPOSE

The Joint Venture shall be formed for the purpose of Provide a description of the products and/or services that the Joint Venture is concerned with, and the objective/purpose of the Joint Venture.

### 3. CONTRIBUTIONS

The total amount of capital contribution which shall be made to the JVC by the parties hereto, shall be as follows:

IMMUNEMED	49%
PRIMA	51%

The Parties hereto shall each make an initial contribution to the Joint Venture as follows:

#### 1. IMMUNEMED's Contribution:

IMMUNEMED shall provide any financial equipment, goods, resources, developments and other valuable contributions.

#### 2. PRIMA's Contribution:

A bank account at WOORI BANK shall be opened by IMMUNEMED on behalf of the Joint Venture, and the financial contributions of the Parties shall be deposited by the due date set forth above. Should the Joint Venture require additional funding, additional financial contributions shall be made equally by the Parties.

### 4. DISTRIBUTION OF PROFITS

Any and all net income accruing to the Joint Venture shall be distributed equally to the Parties or reinvested to the Joint Venture in IMMUNEMED's sole discretion.

### 5. MANAGEMENT

The following individuals in the following positions will comprise the Joint Venture's management (the "Management Team"). The Management Team will be structured such that all decisions for the Joint Venture will be made by IMMUNEMED and then discussed with PRIMA.

Management Team:

- SungHyuk Choi, President of Immunemed (Thailand) Co., Ltd., IMMUNEMED
- Songpol Thammajit, Director of Immunemed (Thailand) Co., Ltd., PRIMA

### 6. RESPONSIBILITIES OF THE PARTIES

The Parties will each have the following responsibilities under the Joint Venture:

IMMUNEMED's Responsibilities:

- ◆ Management of the Joint Venture
- ◆ All decisions

PRIMA's Responsibilities:

- ◆ Management of sales network
- ◆ Bridge between Thailand Government and IMMUNEMED

## 7. NON-EXCLUSIVITY

No exclusivity is formed by virtue of this Joint Venture Agreement and neither Party shall be obligated to make offers to the other related to any business.

## 8. TERM

This Agreement shall commence on the date first written above and remain in full force and effect for an initial period of 2 years (the "Initial Term"). At the end of the Initial Term, this Agreement will automatically renew in one year increments (each, a "Renewal Term"), unless and until this Agreement is terminated in accordance with Section 8 hereinafter.

## 9. TERMINATION

Either Party shall have the right to terminate this Agreement, effective as of the end of the Initial Term or any Renewal Term, by providing the other with written notice of termination at least thirty (30) days prior to the end of such Initial Term or Renewal Term. Neither Party shall have the right to terminate this Agreement at any other time, unless such termination is mutually agreed to by the Parties hereto. The Joint Venture shall terminate upon termination of this Agreement.

## 10. CONFIDENTIAL INFORMATION

The Non-Disclosure Agreement entered into by the Parties as of August 1<sup>st</sup>, 2017 (the "NDA") is applicable to the Joint Venture and shall apply in full force and effect to any and all Confidential Information (as defined in the NDA) exchanged or otherwise accessed by a Party under this Agreement.

## 11. FURTHER ACTIONS

The Parties shall execute any documents and take all appropriate actions as may be necessary to give effect to the Joint Venture.

## 12. ASSIGNMENT

Neither Party shall assign or transfer any of its rights or obligations hereunder without the prior written consent of the other Party, except to a successor in ownership of all or substantially all of the assets of the assigning Party if the successor in ownership expressly assumes in writing the terms and conditions of this Agreement. Any such attempted assignment without written consent will be void. This Agreement shall inure to the benefit of and shall be binding upon the valid successors and assigns of the Parties.

## 13. GOVERNING LAW

This Agreement shall be governed by and construed in accordance with the laws of the State of Korea, without regard to conflicts of law principles.

## 14. COUNTERPARTS

This Agreement may be executed in any number of counterparts, each of which shall constitute an original, and all of which, when taken together, shall constitute one instrument.

## 15. SEVERABILITY

The Parties recognize the uncertainty of the law with respect to certain provisions of this Agreement and expressly stipulate that this Agreement will be construed in a manner that renders its provisions valid and enforceable to the maximum extent possible under applicable law. To the extent that any provisions of this Agreement are determined by a court of competent jurisdiction to be invalid or unenforceable, such provisions will be deleted from this Agreement or modified so as to make them enforceable and the validity and enforceability of the remainder of such provisions and of this Agreement will be unaffected.

## 16. NOTICES

All notices, requests, demands and other communications under this Agreement must be in writing and will be deemed duly given, unless otherwise expressly indicated to the contrary in this Agreement: (i) when personally delivered; (ii) upon receipt of a telephone facsimile transmission with a confirmed telephonic transmission answer back; (iii) three (3) days after having been deposited in the mail, certified or registered, return receipt requested, postage prepaid; or (iv) one (1) business day after having

been dispatched by a nationally recognized overnight courier service, addressed to a Party or their permitted assigns at the address for such Party first written above.

## 17. HEADINGS

Paragraph headings used in this Agreement are for reference only and shall not be used or relied upon in the interpretation of this Agreement.

## 18. ENTIRE AGREEMENT


This Agreement contains the entire agreement and understanding between the Parties, superseding all prior contemporaneous communications, representations, agreements, and understandings, oral or written, between the Parties with respect to the subject matter hereof. This Agreement may not be modified in any manner except by written amendment executed by each Party hereto.

In Witness Whereof, the Parties have caused this Joint Venture Agreement to be duly executed and delivered as of the date first written above.

IMMUNEMED INC.

PRIMA (Thailand) Co., Ltd.

By



By



Name : YoonWon Kim

Name : Songpol Thammajit

Title : President

Title : President

Date : \_\_\_\_\_

Date : \_\_\_\_\_